Table 2 Results of cost utility analyses under scenario B
| Â | New Drug | Standard of Care | Increment |
|---|---|---|---|
a. Treatment of Patients with a Rare Disease | |||
 QALYs | 1.50 | 1.25 | 0.25 |
 Weighted QALYs | 3.00 | 2.50 | 0.50 |
 Costs | $35,000 | $15,000 | $20,000 |
 Incremental cost per QALY gained | $80,000 | ||
 Incremental cost per weighted QALY gained | $40,000 | ||
b. Treatment of a Patients without the Rare Disease | |||
 QALYs | 9.50 | 9.30 | 0.20 |
 Weighted QALYs | 9.50 | 9.30 | 0.20 |
 Costs | $40,800 | $27,000 | $13,800 |
 Incremental cost per QALY gained | $46,000 | ||
 Incremental cost per weighted QALY gained | $46,000 | ||